AstraZeneca and its Maryland-based biologics research and development arm, MedImmune, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending benralizumab as an add-on maintenance treatment in adult patients with a type of severe asthma.